Connect
MJA
MJA

Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia

Philip M Clarke and Edmund M Fitzgerald
Med J Aust 2010; 192 (11): 633-636.

Summary

Objective: To compare changes in the costs of statins following patent expiry in Australia and England, and to estimate projected savings for Australia based on the government and consumers paying prices equivalent to those in England and increased use of generics.

Design: Review of administrative data and predictive models based on recent trends.

Setting: Administrative price and quantity data for the Pharmaceutical Benefits Scheme between January 2002 and October 2009, and comparable information from England.

Main outcome measures: Total government and consumer expenditure on statins whose patent has expired, and projected expenditure on all statins from January 2009  to December 2019 under various scenarios regarding pricing and prescribing trends.

Results: From January 2005 to October 2009, the cumulative loss to the Australian community from paying more than the English price for generic statins was more than $900 million. Expenditure could have been reduced by a further $1087 million if Australia had increased the proportion of generic medications prescribed to match trends in England. Future savings depend on the proportion of statin prescriptions that are subject to lower generic pricing. From January 2009 to December 2019, potential savings from paying English prices could be as high as $3.21 billion, and savings of up to $9.31 billion could be made by paying English prices and using generic statins only.

Conclusion: The current arrangement for pricing statins places a considerable burden on the Australian community. Alternative pricing arrangements that provide incentives to lower statin prices and increase the proportion of generic prescriptions could be highly advantageous.

  • Philip M Clarke1
  • Edmund M Fitzgerald2

  • School of Public Health, University of Sydney, Sydney, NSW.


Acknowledgements: 

We thank Professor Stephen Leeder for his advice on aspects of this study. Philip Clarke was supported by an NHMRC Career Development Award (571122).

Competing interests:

None identified.

  • 1. Sweeny K. Key aspects of the Australian Pharmaceutical Benefits Scheme. Working Paper No. 35. Pharmaceutical Industry Project Working Paper Series. Melbourne: Victoria University of Technology, 2007.
  • 2. Australian Institute of Health and Welfare. Australia’s health 2008. Canberra: AIHW, 2008. (AIHW Cat. No. AUS 99.)
  • 3. Costello P. Intergenerational report 2002–03. Budget Paper No. 5. Canberra: Commonwealth of Australia, 2002.
  • 4. Industry Commission. The pharmaceutical industry. Volume 2: appendices. Report No. 51. Melbourne: Australian Government Publishing Service, 1996.
  • 5. Lofgren H. Reshaping Australian drug policy: the dilemmas of generic medicines policy. Aust New Zealand Health Policy 2007; 4: 11.
  • 6. Beecroft G. Generic drug policy in Australia: a community pharmacy perspective. Aust New Zealand Health Policy 2007; 4: 7.
  • 7. Zweifel P, Breyer F. Health economics. New York: Oxford University Press, 1997.
  • 8. Searles A, Jefferys S, Doran E, Henry DA. Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. Med J Aust 2007; 187: 236-239. <MJA full text>
  • 9. National Prescribing Service. Atorvastatin (Lipitor) for the management of lipid disorders. NPS RADAR fact sheet, December 2005. http://www.nps.org.au/__data/assets/pdf_file/0007/14686/atorvastatin.pdf (accessed Jan 2010).
  • 10. Australian Government Department of Health and Ageing. Fact sheet: Pharmaceutical Benefits Scheme (PBS) reform. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs_reform_02feb07.htm (accessed Jan 2009).
  • 11. Freehills. Atorvastatin in Australia: the latest from the Federal Court. http://www.freehills.com/3200.aspx (accessed Aug 2009).
  • 12. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002; 162: 373-379.
  • 13. Faunce T, Vines T, Gibbons H. New forms of evergreening in Australia: misleading advertising, enantiomers and data exclusivity: Apotex v Servier and Alphapharm v Lundbeck. J Law Med 2008; 16: 220-232.
  • 14. Australian Government Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Commonwealth of Australia, 2008.
  • 15. Medicare Australia. Pricing of PBS medicine. http://www.medicareaustralia.gov.au/provider/pbs/pharmacists/pricing.jsp (accessed Aug 2009).
  • 16. National Health Service Prescription Services. Prescribing information terms. http://www.ppa.nhs.uk//ppa/pi_pmd_report_guidance/prescribing_info_term_files/n.htm (accessed Aug 2009).
  • 17. National Health Service Information Centre. Prescription cost analysis 2008. http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-2008 (accessed Apr 2009).
  • 18. Australian Government. Part 2: expense measures. Health and ageing. In: Budget measures. Budget Paper No. 2. Canberra: Commonwealth of Australia, 2009. http://www.aph.gov.au/budget/2009-10/content/bp2/html/bp2_expense-16.htm (accessed Jul 2009).
  • 19. Bulfone L. High prices for generics in Australia — more competition might help. Aust Health Rev 2009; 33: 200-214.
  • 20. Department of Health and Ageing. Schedule of Pharmaceutical Benefits 1 January 2009. Canberra: Commonwealth of Australia, 2009.
  • 21. Pharmaceutical Management Agency of New Zealand. Tender results. 30 January 2009. http://www.pharmac.govt.nz/2009/01/30/2009-01-30%20Tender%20Notification.pdf (accessed Aug 2009).
  • 22. Walmart. Retail prescription program drug list. Revised 3/3/10. http://i.walmartimages.com/i/if/hmp/fusion/customer_list.pdf (accessed Apr 2010).
  • 23. Stocks N, Ryan P, Allan J, et al. Gender, socioeconomic status, need or access? Differences in statin prescribing across urban, rural and remote Australia. Aust J Rural Health 2009; 17: 92-96.
  • 24. Emerton D. Patent expiries in the US statin market: generics to slash market size by 80 per cent over the next ten years. J Generic Medicines 2006; 4: 73-78.
  • 25. Department of Health. New long-term arrangements for reimbursement of generic medicines: Scheme M. London: DoH, 2005. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4114256.pdf (accessed Jan 2010).
  • 26. de Boer R. PBS reform — a missed opportunity? Aust Health Rev 2009; 33: 176-185.
  • 27. Faunce TA, Lofgren H, Harvey K, Johnson K. Tendering for low cost generics in Australia. Health Issues 2006; 87: 26-29.
  • 28. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Technology Appraisal 94. London: NICE, 2006.
  • 29. Moon JC, Bogle RG. Switching statins. BMJ 2006; 332: 1344-1345.
  • 30. Gumbs PD, Verschuren WM, Souverein PC, et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol 2007; 64: 680-685.
  • 31. Australian Government. Budget strategy and outlook. Budget Paper No. 1. Canberra: Commonwealth of Australia, 2009. http://www.budget.gov.au/2009-10/content/overview/html/index.htm (accessed Aug 2009).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.